مهندس ذكاء اصطناعي يصنع لقاح mRNA محلي الصنع ينقذ الكلب ويثير نقاشات ساخنة: تقلص الورم لكن لم يتم الشفاء بعد، اختناقات التنظيم أصبحت محور التركيز

According to CoinWorld, based on monitoring by 1M AI News, Sydney-based machine learning engineer Paul Conyngham used ChatGPT and DeepMind’s AlphaFold to self-learn mRNA vaccine design, creating a custom vaccine for Rosie, a rescue dog suffering from mast cell cancer. He collaborated with the University of New South Wales (UNSW) RNA Research Institute to complete the vaccine design and administered the injection at the Gatton Veterinary School of the University of Queensland. After the injection, one of Rosie’s tumors significantly shrank. Veterinarian Paola Allavena stated, “The tumor has shrunk by about half.” This story has recently been widely circulated on social media as “AI cured the dog’s cancer.” However, according to the original report published by UNSW, Rosie’s cancer is still progressing (“Rosie’s cancer is progressing”), and a cure is still distant. Biomedical engineer Patrick Heizer pointed out on X that manufacturing a single mRNA vaccine is “trivially easy” technically, but the real challenge and expense lie in proving the vaccine’s safety and efficacy through randomized controlled trials, which has not yet been achieved. Conyngham also noted that the biggest obstacle in the entire process was not vaccine design but ethical approval: he spent three months and two hours every night drafting a 100-page ethics approval document, “more difficult than making the vaccine.” Biology author Ruxandra Teslo cited a similar experience of GitLab co-founder Sid Sijbrandij (self-funded exploration of experimental therapy after osteosarcoma relapse, no recurrence since 2025), believing that regulatory bureaucrats in early clinical trials are the core bottleneck hindering the implementation of personalized medicine.